Serina Therapeutics signs $25 million equity purchase deal with Roth Principal Investments
The Alabama biotech gained discretionary access to sell newly issued shares over 36 months under an agreement dated August 21, 2026.
SEC filing
Latest
4 stories
Wednesday, August 26
Monday, August 24
Serina Therapeutics registers 12.5 million shares for Roth Principal Investments resale
The Huntsville biotech filed an S-1 on August 24, 2026 to cover potential stock sales under a new $25 million equity purchase agreement.
SEC filing
Thursday, August 13
Serina completes Cohort 1 dosing in SER-252 Parkinson's trial ahead of schedule
The company reported Cohort 1 enrollment finished early, with single-ascending-dose top-line data still targeted for the first half of 2027.
SEC filing
Thursday, July 23
Serina names Trevi executive Farrell Simon to board, days after amending CEO's pay pact
The Huntsville biotech disclosed a July 19 amended CEO employment agreement before announcing a July 22 board appointment tied to its Parkinson's program SER-252.
SEC filing (2)